INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1012 (Consolidated Modification and Enforcement Proceeding)]

Certain Magnetic Data Storage Tapes and Cartridges Containing the Same Notice of Institution of Modification Proceeding

AGENCY: U.S. International Trade

Commission. **ACTION:** Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to institute a modification proceeding relating to the March 8, 2018 limited exclusion order and cease and desist orders issued in the above-referenced investigation.

FOR FURTHER INFORMATION CONTACT:

Megan M. Valentine, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708-2301. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted the original investigation on July 1, 2016, based on a complaint filed by Fujifilm Corporation of Tokyo, Japan, and Fujifilm Recording Media U.S.A., Inc. of Bedford, Massachusetts (collectively, "Fujifilm"). 81 FR 43243-44 (July 1, 2016). Pertinent to this action, the complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 ("section 337"), in the sale for importation, importation, and sale within the United States after importation of certain magnetic data storage tapes and cartridges containing the same by reason of infringement of, inter alia, claims 1, 4-9, 11 and 14 of U.S. Patent No. 6,641,891 ("the '891 patent"). The Commission's Notice of Investigation

named as respondents Sony Corporation of Tokyo, Japan, Sony Corporation of America of New York, New York, and Sony Electronics Inc. of San Diego, California (collectively, "the Sony respondents"). The Office of Unfair Import Investigations ("OUII") was also named as a party to the investigation.

On March 8, 2018, the Commission found a section 337 violation as to the '891 patent and issued a limited exclusion order ("LEO") and cease and desist orders ("CDOs") to each of the Sony respondents. 83 FR 11245-47 (March 14, 2018). The LEO generally prohibits the Sony respondents from importing certain magnetic data storage tapes and cartridges containing the same that infringe the '891 patent, with certain exceptions related to service and repair and verification testing. The CDOs prohibit the Sony respondents from importing, selling, marketing, advertising, distributing, transferring (except for exportation) certain magnetic data storage tapes and cartridges containing the same that infringe the '891 patent, and soliciting United States agents or distributors for these activities.

On May 9, 2018, Fujifilm filed a complaint requesting that the Commission institute a formal enforcement proceeding under Commission Rule 210.75 to investigate alleged violation of the CDOs by the Sony Respondents, as well as Sony Storage Media Solutions Corporation, Sony Storage Media Manufacturing Corporation, Sony DADC US Inc., and Sony Latin America Inc. (collectively, "Sony"). On June 13, 2018, the Commission instituted the enforcement proceeding. 83 FR 27626-27 (June 13, 2018). OUII was also named as a party in the enforcement proceeding.

On July 23, 2018, Sony filed a request for an advisory opinion and a petition for modification of the remedial orders to clarify that certain of its redesigned tape products are outside the scope of the remedial orders. On August 2, 2018, Fujifilm filed a response, opposing both Sony's request and petition.

Having examined the request and petition, as well as the supporting documents, the Commission has determined to institute a modification proceeding, pursuant to Commission Rule 210.76(b) (19 CFR. 210.76(b)), to determine whether the LEO and CDOs issued in the underlying investigation should be modified to exclude certain of Sony's redesigned tape products. The Commission has further determined to delegate the modification proceeding to the presiding administrative law judge and to consolidate that proceeding with the ongoing enforcement proceeding.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission. Issued: August 17, 2018.

Lisa Barton,

Secretary to the Commission.
[FR Doc. 2018–18155 Filed 8–22–18; 8:45 am]
BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-471P]

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2018

AGENCY: Drug Enforcement Administration, Department of Justice. **ACTION:** Notice with request for comments.

SUMMARY: The Drug Enforcement Administration (DEA) proposes to adjust the 2018 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before September 24, 2018. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the Federal Register. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the Federal Register a final order establishing the 2018 adjusted aggregate

production quotas for schedule I and II controlled substances, and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA-471P" on all correspondence, including any attachments. The Drug **Enforcement Administration encourages** that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia

FOR FURTHER INFORMATION CONTACT:

Thomas D. Sonnen, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at http://www.regulations.gov. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the

phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to http:// www.regulations.gov may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at http://www.regulations.gov for easy reference.

Legal Authority and Background

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100.

The DEA established the 2018 aggregate production quotas for substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on November 8, 2017 (82 FR 51873). That notice stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

Analysis for Proposed Adjusted 2018 Aggregate Production Quotas and Assessment of Annual Needs

The DEA proposes to adjust the established 2018 aggregate production quotas and assessment of annual needs for certain schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2018 to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed adjustment, the Acting Administrator has taken into account the criteria in accordance with 21 CFR 1303.13 (adjustment of aggregate production quotas for controlled substances) and 21 CFR 1315.13 (adjustment of the assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA determined whether to propose an adjustment of the aggregate production quotas and assessment of annual needs for 2018 by considering: (1) Changes in the demand for that class or chemical, changes in the national rate of net disposal of the class or chemical, and changes in the rate of net disposal of the class or chemical by registrants holding individual manufacturing quotas for the class; (2) whether any increased demand for that class or chemical, the national and/or individual rates of net disposal of that class or chemical are temporary, short term, or long term; (3) whether any increased demand for that class or chemical can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand for that class or chemical will result in excessive inventory accumulation by all persons registered to handle that class or chemical; and (5) other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements, as the Acting Administrator finds relevant. These quotas do not include imports of controlled substances for use in industrial processes.

The Acting Administrator also considered updated information obtained from 2017 year-end inventories, 2017 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to the DEA after the initial aggregate production quotas and assessment of annual needs had been established. Other factors the Acting Administrator considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of

both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed adjusted 2018 assessment of annual needs, the DEA used the calculation methodology previously described in the 2010 and 2011 established assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively).

The Acting Administrator, therefore, proposes to adjust the 2018 aggregate production quotas for certain schedule I and II controlled substances and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class	Established 2018 quotas (g)	Proposed revised 201 quotas (g)
Temporarily Scheduled Substances		
I-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide	N/A	25.
I-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide	N/A	25.
Cyclopropyl Fentanyl	N/A	20.
Fentanyl related substances	N/A	25.
sobutyryl Fentanyl	N/A	25.
Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate	N/A	25.
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	N/A	25.
Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate	N/A	
Ocfentanil	N/A	_
Para-flourobutyryl fentanyl	N/A	
Fetrahydrofuranyl fentanyl	N/A	5.
/aleryl fentanyl	N/A	25.
Schedule I		
I-[1-(2-Thienyl)cyclohexyl]pyrrolidine	Zero	
I-(1-Phenylcyclohexyl)pyrrolidine	10	15.
I-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	zero	10.
-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	30	no change.
I-(5-Fluoropentyl)-3-(2-iodobenzóyl)indole (AM694)	30	no change.
-[1-(2-Thienyl)cyclohexyl]piperidine	15	no change.
-Benzylpiperazine	25	no change.
-Methyl-4-phenyl-4-propionoxypiperidine	2	10.
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	30	no change.
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	30	no change.
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)	30	no change.
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)	30	no change.
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-	30	no change.
(4-bioino-2,5-dimethoxyphenyi)-iv-(2-methoxybenzyi)ethanamine (25b-ivbowie, 26-b-ivbowie, 25b, oimbi-	30	no change.
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	30	no change.
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82).	25	no change.
2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	30	no change.
2-(4-lodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)	30	no change.
2,5-Dimethoxy-4-ethylamphetamine (DOET)	25	no change.
2,5-Dimethoxy-4-n-propylthiophenethylamine	25	no change.
2,5-Dimethoxyamphetamine	25	no change.
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	30	no change.
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	30	no change.
3,4,5-Trimethoxyamphetamine	30	no change.
3,4-Methylenedioxyamphetamine (MDA)	55	no change.
3,4-Methylenedioxymethamphetamine (MDMA)	50	no change.
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	40	no change.
3,4-Methylenedioxy-N-methylcathinone (methylone)	40	no change.
,4-Methylenedioxypyrovalerone (MDPV)	35	no change.
-FMC; 3-Fluoro-N-methylcathinone	25	no change.
B-Methylfentanyl	30	no change.
l-Methylthiofentanyl	30	no change.
I-Bromo-2,5-dimethoxyamphetamine (DOB)	30	no change.
I-Bromo-2,5-dimethoxyphenethylamine (2-CB)	25	no change.
-Fluoroisobutyryl fentanyl	30	no change.
-FMC; Flephedrone	25	no change.
-MEC; 4-Methyl-N-ethylcathinone	25	no change.
-Methoxyamphetamine	150	no change.
I-Methyl-2,5-dimethoxyamphetamine (DOM)	25 25	no change.

Methyl-c-pyroldinopropiophenone (4-MoPPP)	Basic class	Established 2018 quotas (g)	Proposed revised 201 quotas (g)
Methyl-c-pyroldinopropiophenone (4-MoPPP)	4-Methyl-N-methylcathinone (mephedrone)	45	no change.
1.1 - Dimetriyol-(2-(11,83)-3-)-tydroxyycolobaxyl-phenol (canabolycichexanol or CP-47,497 C8-homolog)			
1,1-Dimethylocity)-2[(18,33)-3-hydroxyyciohexyl-phenol (cannabicyclohexyl-phenol or CP-47,497 C8-homolog)	5-(1,1-Ďimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	50	no change.
-AMB (methyl 2 (1-16-fluoropentyl) - H-indazole-3-carboxamido) - 30 no change AMB (ANEAR) (N-AGARMANTA-1yl) - 1-5 (huropentyl) - H-indazole-3-carboxamide)	5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog)	40	no change.
APINACA, 5F-ARC484 (N-(Adamantan-1-yl)-1-(-fuluropentyl)-1H-indazole-3-carboxamide) 10 on change. 12 con change. 12 con change. 12 con change. 13 con change. 14 con change. 15 con change. 16 con change. 17 con change. 18 con cha	F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30	no change.
Function	F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	30	no change.
Filterory Life Act	F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)		
Welthoxy 3-4methylenedioxyamphetamine 25 no change. Welthoxy N. Ndimethyltypatmine 25 no change. Verbina V. Ndimethyltypatmine 25 no change. S. ChildiNACA 30 no change. S. PINACA 30 no change. S. PINACA 30 no change. S. PINACA 30 no change. S. PINACA (A). (Al-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) 100 no change. sely Fernatnyl 90 no change. no change. no change. no change. sely Fernatnyl 90 no change.			no change.
Methoxy-N-N-discopropytryptamine 25 no change, whethoxy-N-N-dimethyltyptamine 25 no change, so chang	-yl](2,2,3,3-tetramethylcyclopropyl)methanone		
Methoxy-N-N-dimethytryptamine	-Methoxy-3,4-methylenedioxyamphetamine	25	
S-CHMINACA			
PEPURIACA 50 00 change 50 00 change 50 50 50 50 50 50 50 5			
PFINACA PFI-framino 3.3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) 100			
DB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) co change.			
Peti Fernary			
a change			
elyidinydrocodeine			
relymerhadol yrighen and yright for a change. Sephen ACA (W1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1/H-indazole-3-carboxamide)			
ry Fentanyl	• •		
Dis-PINACÁ (M-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1-Hindazole-3-carboxamide) 50 no change. 4-7921 30 no change. ylprodine 2 no change. Jha-Ethyltryptamine 25 no change. shameprodine 2 no change. shamelhiddel 2 no change. shamelhitylitylentamyl 30 no change. sha-Methythlofentanyl 30 no change. sha-Methythlofentanyl 30 no change. sha-Methythlofentanyl 30 no change. sha-Methythlofentanyl 25 no change. sha-Methythlofentanyl 25 no change. share-Pyrrolidinopentiophenone (α-PPP) 25 no change.	·		
1-7921			
ylprodine 2 no change 2 no change 3 no change			
nacetymethadol 2 no change. namethadol 2 no change. shameprodine 2 no change. shamethadol 30 no change. shamethyfichiorentaryl 30 no change. shaw Methyfthyptamine (AMT) 25 no change. shaw Pyrrolidinobuliophenone (α-PBP) 25 no change. shape-Pyrrolidinopentiophenone (α-PBP) 20			
π/π-EINItytyptamine 25 no change, and change point of ham be profiled in the profiled	\mathcal{L}_{i}		
nhameprodine 2 no change. nhamelhadol 2 no change. nhamelhity/fentanyl 30 no change. nhamelhity/fentanyl 30 no change. nhamelhity/fentanyl 25 no change. nhamely/finity	•		
phamethadol 2 no change. pha-Methylthioftanaly 30 no change. pha-Methylthyltpamine (AMT) 25 no change. pha-Pyrrolidinobutiophenone (α-PBP) 25 no change. pha-Pyrrolidinopentiophenone (α-PVP) 25 no change. linces 25 no change. lacest/imethadol 2 no change. ta-hydroxyfentanyl 30 no change. tameprodine 2 no change. tameprodine 2 no change. tameprodine 2 no change. tameprodine 2 no change. tamperodine 2 no change. tamperodine 2 no change. tamperodine 2 no change.	, , ,,,		
sha-Methylifentanyl 30 no change. sha-Methylitryptamine (AMT) 25 no change. sha-Pryrolidinobutiophenone (c-PBP) 25 no change. sha-Pryrolidinobutiophenone (c-PVP) 25 no change. sha-Pryrolidinobutiophenone (c-PVP) 25 no change. shincores 30 no change. star-bydroxy-amethyltentanyl 30			
oha-Methylthiofentanyl 30 no change. oha-Methyltptamine (AMT) 25 no change. oha-Pyrrolidinobutiophenone (α-PVP) 25 no change. ninorex 25 no change. NINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1/Hindazole-3-carboxamide) 25 no change. stacetylmethadol 30 no change. ta-Hydroxy-methylfentanyl 30 no change. ta-Hydroxy-methylfentanyl 30 no change. ta-Hydroxy-methylfentanyl 30 no change. tameprodine 2 no change. tameprodine 2 no change. tameprodine 2 no change. tataprodine 2 no change. foterine 3 no change. tataprodine 2 no change. tataprodine 2 no change. foterine 3 no change. taptine 2 no change. tapting 2 no change. tapting 3 no change. <tr< td=""><td>·</td><td></td><td></td></tr<>	·		
oha-Methylityptamine (AMT) 25 no change. oha-Pyrriolidinopentiophenoe (α-PBP) 25 no change. oha-Pyrriolidinopentiophenoe (α-PVP) 25 no change. nilnoex 25 no change. inilnoex 25 no change. nzylmophine 25 no change. nzylmophine 30 no change. tacetylmethadol 2 no change. ta-Hydroxy-amethylfentanyl 30 no change. ta-Hydroxythiofentanyl 30 no change. tatamethadol 4 no change. tatamethadol 3 no change. tatamethadol <td>, , ,</td> <td></td> <td></td>	, , ,		
υλα-Pyrrolidinobutiophenone (α-PBP) 25 no change. υλα-Pyrrolidinopentiophenone (α-PVP) 25 no change. υπον (A KB48 (I/-(1-adamantyl)-1-pentyl-1/Hindazole-3-carboxamide) 25 no change. υπογμηστρήπο 30 no change. stacetylmethadol 2 no change. sta-Hydroxy-a-methylfentanyl 30 no change. sta-Hydroxythiofentanyl 30 no change. stamethadol 4 no change. stamethadol 4 no change. stamethadol 4 no change. staprodine 3 no change. stop typyl fentanyl 3 no change. stop typy			
υπα-Pyrolidinopentiophenone (α-PVP) 25 no change. ninorex 25 no change. ninorex 25 no change. nnzylmorphine 30 no change. nnzylmorphine 30 no change. ta-tydroxy3-methylfentanyl 30 no change. ta-Hydroxythiofentanyl 30 no change. ta-tydroxythiofentanyl 30 no change. tameprodine 2 no change. tameprodine 2 no change. taferrodine 2 no change. tofotenine 3 no change. tylyl fentanyl 30 no change. delene methylbromide 30 no change. delene methylbromide 30 no change. sepomorphine 25 no change. sepomorphine 3.8225 no change. etnoxin			
Indicases 25 no change 25 no c			
NRCA AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide)			
International Content			
stacety/methadol 2 no change. tat-Hydroxy-3-methylfentanyl 30 no change. tat-Hydroxyfindentanyl 30 no change. tat-Hydroxyfindentanyl 30 no change. tat-Hydroxyfindentanyl 2 no change. tatamethadol 4 no change. tataprodine 2 no change. indepoline 3 no change. indepoline 3 no change. indepoline 25 no change. indepoline 30 no change. indepoline 25 no change. indepoline 25 no change. indepoline 325 no change. indepoline 325 no change. indepoline 3 no change.			
tra-Hydroxy3-methylfentanyl 30 no change. tra-Hydroxythiofentanyl 30 no change. tra-Hydroxythiofentanyl 30 no change. tra-Hydroxythiofentanyl 2 no change. tramethadol 4 no change. tramethadol 2 no change. trytone 25 no change. trytylene 25 no change. trytyl fentanyl 30 no change. trytyl fentanyl 25 no change. trytyl fentanyl 25 no change. trytyl fenta	· ·		
tat Hydroxyfentanyl 30 no change. tat Hydroxythiofentanyl 30 no change. tamethadol 4 no change. tatagrodine 2 no change. tatoprodine 2 no change. fotenine 3 no change. tylone 25 no change. tylone 24 no change. tylone 24 no change. deline methylbromide 30 no change. deline methylbromide 30 no change. desomorphine 25 no change. apromide 25 no change. esomorphine 25 no change. peroxin 8,225 no change. fenoxin 8,225 no change. promide 25 no change. fenoxin 8,225 no change. fenoxin 8,225 no change. prophydromorphine 1,000,160 no change. prophine 30 no change. prophydromorphine 30 no change. prophyline <td></td> <td></td> <td></td>			
trat—Hydroxythiofentanyl 30 no change. stameprodine 2 no change. stapprodine 2 no change. fotenine 3 no change. totenine 3 no change. tryly fentanyl 30 no change. deline-N-oxide 30 no change. seomorphine 25 no change. seomorphine 25 no change. serrormide Zero 20. ethylthriambutene 25 no change. tenoxin 8,225 no change. nydromorphine 3,25 no change. pipianone 5 50. pripine 30 no change. pripine 30 no change. pripine 30 no change. pripine 30 no change. pripine <td>, , , ,</td> <td></td> <td></td>	, , , ,		
etameprodine 2 no change tamethadol 4 no change tateprodine 2 no change fotenine 3 no change tytylone 25 no change tytyl fentanyl 30 no change tytyl fentanyl 30 no change tytyl fentanyl 30 no change odeine methylbromide 30 no change no change 25 no change promide Zero 25 ethyltrythamine tenory 25 no change enoxin 8,225 no change hydromorphine 35 50 proprine 35 50 proprine 30 no change	• • •		
Internation	etameprodine		
Internation	etamethadol		no change.
trylyl fentanyl 30 no change. tyryl fentanyl 30 no change. tyryl fentanyl 30 no change. deline methylbromide 30 no change. odeine-N-oxide 192 no change. sepromorphine 25 no change. apromide Zero 20. ethyltryptamine 25 no change. sport 8,225 no change. sport 1,000,160 no change. sport 35 50. sport 30 no change.	etaprodine	2	
dryryl fentanyl 30 no change. thinone 24 no change. odeine methylbromide 30 no change. odeine-N-oxide 192 no change. esomorphine 25 no change. apromide Zero 20 ethyltriptamine 25 no change. fenoxin 8,225 no change. hydromorphine 1,000,160 no change. methyltryptamine 35 50. pipanone 5 no change. orphine 30	ufotenine	3	no change.
dryryl fentanyl 30 no change. thinone 24 no change. odeine methylbromide 30 no change. odeine-N-oxide 192 no change. esomorphine 25 no change. apromide Zero 20 ethyltriptamine 25 no change. fenoxin 8,225 no change. hydromorphine 1,000,160 no change. methyltryptamine 35 50. pipanone 5 no change. orphine 30	utylone		
atthinone 24 no change. odeine methylbromide 30 no change. odeine-N-oxide 192 no change. psomorphine 25 no change. apromide Zero 20. ethylthiambutene 25 no change. ethyltryptamine 8,225 no change. fenoxin 8,225 no change. hydromorphine 1,000,160 no change. pipanone 5 no change. porphine 30 no change. promine 37,130,000 no change. promine 45 no change. promine 30 no change. <td>utyryl fentanyl</td> <td></td> <td></td>	utyryl fentanyl		
Adeine methylbromide 30 100 change 192 192 192 193 193 194 194 195 194 195	athinone	24	
192 no change 25 no change 25 no change 20 25 no change 20 20 20 20 20 20 20 2	odeine methylbromide	30	no change.
Appromide	odeine-N-oxide	192	no change.
Ethylthiambutene	esomorphine	25	no change.
Dethyltryptamine Contange Renoxin Reno	iapromide	Zero	20.
fenoxin 8,225 no change. hydromorphine 1,000,160 no change. methyltryptamine 35 50. pipanone 5 no change. prethylline 30 no change. prethylline 30 no change. promma-Hydroxybutyric acid 37,130,000 no change. peroin 45 no change. prodromorphinol 40 no change. prograine 2 no change. pVH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. pVH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. pVH-074 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 45 no change. product 30 no change. no change. product 35 no change. no change. no change. product 35 no change. no change. no change. no change. product 35 no change. no	iethylthiambutene	Zero	20.
hydromorphine	iethyltryptamine	25	
methyltryptamine 35 50. pipanone 5 no change. orphine 30 no change. inethylline 30 no change. irranyl fentanyl 30 no change. irranyl fentanyl 30 no change. irranyl fentanyl no change. no change. irranyl fentanyl 45 no change. irranyl fentanyl no change. no change. irranyl fentanyl 45 no change. irranyl fentanyl 45 no change. irranyl fentanyl 45 no change. irranyl fentanyl 30	ifenoxin		
Dipanone	ihydromorphine	1,000,160	
porphine 30 no change prethylline 30 no change prethylline 30 no change preding 37,130,000 no change proin 45 no change proin 40 no change proin 2 no change proin 30 no change proin 2 no change proin 30 no change proin 30 no change proin 35 no change proin 35 no change proin 35 no change proin 45 no change proin 45 <td< td=""><td>methyltryptamine</td><td></td><td></td></td<>	methyltryptamine		
Indicates the proof of the pr	ipipanone		
Tranyl fentanyl 30 100 change 37,130,000 17,130	torphine		
mma-Hydroxybutyric acid 37,130,000 no change. peroin 45 no change. prodroxypethidine 2 no change. prograine 30 no change. pVH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. pVH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. pVH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. pVH-074 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	enethylline		
Addition	uranyl fentanyl		
dromorphinol	amma-Hydroxybutyric acid	1	
rdroxypethidine 2 no change. ogaine 30 no change. vH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. vH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. vH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. vH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	eroin		
ogaine 30 no change. VH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. vH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. vH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. vH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	ydromorphinol		
VH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. VH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. VH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. VH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	ydroxypethidine		
VH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. VH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. VH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	ogaine		
VH-073 (1-Butýl-3-(1-naphthoyl)indole) 45 no change. VH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change.	WH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)		
VH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)	WH-019 (1-Hexyl-3-(1-naphthoyl)indole)		
	WH-073 (1-Butyl-3-(1-naphthoyl)indole)		
VH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)	WH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) WH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)		

Basic class	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	35	no change.
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)		no change.
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)	30	no change.
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)	30	no change.
Lysergic acid diethylamide (LSD)	40	no change.
MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-inda- zole-3-carboxamide).	30	no change.
MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate).	30	no change.
MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30	no change.
Marihuana	443,680	1,140,216.
Mecloqualone	30	no change.
Mescaline	25	no change.
Vethaqualone	60	no change.
Vethcathinone	25	no change.
Methyldesorphine	5	no change.
Methyldihydromorphine	2	no change.
Morphine methylbromide		no change.
Morphine methylsulfonate	5	no change.
Morphine-N-oxide		no change.
V,N-Dimethylamphetamine	25	no change.
Naphyrone	25	no change.
V-Ethyl-1-phenylcyclohexylamine	_ 5	no change.
N-Ethyl-3-piperidyl benzilate		10.
V-Ethylamphetamine	24	no change.
V-Hydroxy-3,4-methylenedioxyamphetamine		no change.
Noracymethadol	2	no change.
lorlevorphanol	55	no change.
lormethadone	2	no change.
lormorphine	40	no change.
Para-fluorofentanyl	25	no change.
Parahexyl	5	no change.
PB-22; QUPIC	20	no change.
Pentedrone	25	no change.
Pentylone	25	no change.
Phenomorphan	2	no change.
Pholcodine	5	no change.
Psilocybin	30	no change.
Silocyn		no change.
RR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)		no change.
R-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)	30	no change.
etrahydrocannabinols	384,460	no change.
hiofentanyl	25	no change.
HJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)	30	no change.
ilidine	25	no change.
rimeperidine	2	no change.
JR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	25	no change.
J-47700	30	no change.
Schedule II	1	T
-Phenylcyclohexylamine	4	15.
-Piperidinocyclohexanecarbonitrile	4	25.
-Anilino-N-phenethyl-4-piperidine (ANPP)	1,342,320	no change.
Ifentanii	6,200	no change.
Alphaprodine	2	no change.
mobarbital	20,100	no change.
mphetamine (for conversion)	11,280,000	12,700,000.
mphetamine (for sale)	39,856,000	no change.
nileridine	Zero	20.
Carfentanil	20	no change.
Cocaine	92,120	no change.
Codeine (for conversion)	15,040,000	12,900,000.
Codeine (for sale)	40,015,000	no change.
Dextropropoxyphene	35	no change.
Dihydrocodeine	264,140	no change.
Dihydroetorphine	2	no change.
Diphenoxylate (for conversion)	14,100	no change.
	770,800	no change.
Diphenoxylate (for sale)	770,000	
Diphenoxylate (for sale)	88,134	no change.

Rorphine hydrochloride entanyl	Established 2018 quotas (g)	Proposed revised 2018 quotas (g)
slutethimide lydrocodone (for conversion) lydrocodone (for sale) lydrocodone (for sale) lydrocodone (for sale) lydrocodone (for sale) lydromorphone sovo-alphacetylmethadol (LAAM) leveromethorphan leverophano listedsamfetamine leperidine Intermediate-A leperidine Intermediate-B leperidine Intermediate-B leperidine Intermediate-B lethadone (for sale) lethylphenidate lethylphenid	32	
lydrocodone (for conversion) ydrocodone (for sale) sidexamfetamine deperidine Intermediate -A deperidine Intermediate -B detazocine dethadone (for sale) lethadone (for sale) lethadone (for sale) dethadone intermediate dethamphetamine 346,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] dethylphenidate loroxymorphone (for conversion) dorphine (for conversion) dorphine (for conversion) plum (powder) plum (powder) plum (powder) plum (fincture) hyphomorphone (for conversion) bxycodone (for conversion) bxymorphone (for sale) bxymorphone (for sale) hyphomorphone (for sale) henacocine henenyelcidine henacocine henenyelcidine henacemorphan letentientanil letenotabrital lufentanil lagentadol hebaline List I Chemicals	1,342,320	
lydrocodone (for sale) somethadone sometha	2	no change.
iydromorphone somethadone evo-alphacetylmethadol (LAAM) evomethorphan evo-alphacetylmethadol (LAAM) evomethorphan evorphanol sidexamfetamine deperidine Intermediate-A deperidine Intermediate-B eleperidine Intermediate-B eleperidine Intermediate-C detazocine dethadone (for sale) dethadone (for sale) elethadone (for sale) elethadone Intermediate dethamphetamine elethamphetamine elethamphetamine elethamphetamine elethamphetamine (for sale) elethamphetamphetamine (for sale) elethamphetamph	114,680	no change.
somethadone evo-alphacety/methadol (LAAM) evo-alphacety/methadol (LAAM) evorethorphan evorphanol sisdexamfetamine deperidine Intermediate-A deperidine Intermediate-B deperidine Intermediate-C fetazocine lethadone (for sale) lethadone (for sale) lethadone Intermediate dethamphatamine 346,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] fethylphenidate forphine (for conversion) forphine (for conversion) forphine (for conversion) forphine (for conversion) foroxymorphone (for conversion) foroxymorphone (for conversion) foroxymorphone (for conversion) forphine (for conver	50,348,280	44,710,000.
evo-alphacetylmethadol (LAAM) evorphanol sidexamfetamine deperidine Intermediate-A deperidine Intermediate-B deperidine Intermediate-B deperidine Intermediate-C detaccine detaccine dethadone (for sale) dethadone Intermediate dethamphetamine 346,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] Methylphenidate dorphine (for conversion) dorphine (for conversion) doroxymorphone (for conversion) foroxymorphone (for conversion) foroxymorphone (for conversion) bycodone (for sale) bylpum (incture) bylpum (incture) bylpum (grower) bylpum (for conversion) byxycodone (for sale) byxymorphone (for conversion) byxymorphone (for sale)	4,547,720	
evomethorphan evorphanol sidexamidetamine severphanol sidexamidetamine sev	30	no change.
evorphanol isotexamfetamine leperidine Intermediate-A leperidine Intermediate-B leperidine Intermediate-B leperidine Intermediate-B leperidine Intermediate-B lettradone (for sale) lettradone Intermediate lettramphetamine lettramphetamine lettramphetamine lettramphetamine lettramphetamine lettramphetamine lettramphetamine lettramphetamine (for sale) lettramphetamine (for sale) lettramphetamine (for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] ### Application lettramphetamine lettramphetamine lettramphetamine (for sale) lettramphetamine (for conversion) loroxymorphone (for sale) loroxymorphone (for conversion) loroxymorph	5	no change.
isclexamfetamine deperidine intermediate-A deperidine intermediate-B deperidine intermediate-B deperidine intermediate-C defeatacoine determediate-C defeatacoine determediate-B defended intermediate determined intermediate defended intermediate defended intermediate defended intermediate defended de	30	2,200.
Reperidine Intermediate-A Reperidine Intermediate-B Reperidine Intermediate-B Reperidine Intermediate-C Relatazocine Rethadone (for sale) Rethadone (for sale) Rethadone Intermediate Rethamphetamine Rethamphetamphetamine Rethamphetamphetamine Rethamphetamphetamine Rethamphetamphetamine Rethamphetamphetamine Rethamphetamine Rethamphetamphetamine Rethamphetamine Rethamphetamphetamine Rethamphetamphetamphetamine Rethamphet	12,126 17,869,000	
Intermediate A		
Intermediate Base	2,717,540 5	1,913,148. 30.
Intermediate - C Intermediate - Inter	30	no change.
Methadone (for sale)	5	30.
Methadone (for sale) Methadone Intermediate Methadone Intermediate Methadone Intermediate Methadone Intermediate Methamphetamine 346,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] Methylphenidate Morphine (for conversion) Morphine (for sale) Malbilone Moroxymorphone (for conversion) Moroxymorphone (for conversion) Moroxymorphone (for sale) Moroxymorphone (for conversion) Moxycodone (for canle) Moxycodone (for sale) Moxymorphone (for conversion) Moxymorphone (for conversion) Moxymorphone (for sale) Mo	15	no change.
Methadone intermediate Methamphetamine 346,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] Methylphenidate Morphine (for conversion) Morphine (for conversion) Morphine (for sale) Moroxymorphone (for conversion) Moroxymorphone (f	22,278,000	no change.
Methamphetamine	24,064,000	no change.
Ade,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 564,000 grams for conversion to a schedule III product; and 36,754 grams for methamphetamine (for sale)] Methylphenidate	1,446,754	no change.
Morphine (for conversion) Morphine (for sale) Iabilone Morphine (for conversion) Morphine (for conversion) Morphine (for conversion) Morphine (for conversion) Morphyshop (for conversion) Morphyshop (for sale) Morphyshop (for sale) Morphyshop (for conversion) Morphyshop (for conversion) Morphyshop (for sale)	methampheta	mine mostly fo
Morphine (for conversion) Morphine (for sale) Iabilone Morphine (for conversion) Morphine (for conversion) Morphine (for conversion) Morphine (for conversion) Morphyshop (for conversion) Morphyshop (for sale) Morphyshop (for sale) Morphyshop (for conversion) Morphyshop (for conversion) Morphyshop (for sale)	64.600.000	no change.
Morphine (for sale) labilone loroxymorphone (for conversion) loroxymorphone (for sale) loripavine (for conversion) loxycodone (for conversion) loxycodone (for sale) loxymorphone (for conversion) loxymorphone (for sale) lox	4,089,000	
loroxymorphone (for conversion) loroxymorphone (for sale) Dipium (powder) Dipium (incture) Dripavine Dxycodone (for conversion) Dxycodone (for sale) Dxymorphone (for conversion) Dxymorphone (for sale) Phenazocine Phenazocine Phenazocine Phenylacetone Bacemerthorphan Bacemorphan Bac	33,958,440	31,456,000.
loroxymorphone (for conversion) loroxymorphone (for sale) Dipium (powder) Dipium (incture) Dripavine Dxycodone (for conversion) Dxycodone (for sale) Dxymorphone (for conversion) Dxymorphone (for sale) Phenazocine Phenazocine Phenazocine Phenylacetone Bacemerthorphan Bacemorphan Bac	31,000	62,000.
Opium (powder) Dipavine (tincture) Dripavine (tor conversion) Doxycodone (for conversion) Doxymorphone (for conversion) Doxymorphone (for sale) Dentobarbital (thenazocine (th	14,044,540	16,440,000.
Dripavine (Tincture) Dripavine (Dripavine (D	376,000	no change.
Oripavine Oxycodone (for conversion) Oxycodone (for sale) Oxymorphone (for conversion) Oxymorphone (for conversion) Oxymorphone (for sale) Oxymorphone (for sale	84,600	no change.
Oxycodone (for conversion) Oxycodone (for sale) Oxymorphone (for conversion) Oxymorphone (for sale) Oxymorphone (f	564,000	no change.
Oxycodone (for sale) Oxymorphone (for conversion) Oxymorphone (for sale) Oxymorphone (for s	24,534,000	no change.
Oxymorphone (for conversion) Oxymorphone (for sale) Oxymorphone (for	2,453,400	no change.
Oxymorphone (for sale) Pentobarbital Phenazocine Phencyclidine Phenmetrazine Phenylacetone Racemethorphan Remifentanil Recobarbital Surfentanil Rapentadol Phebaine List I Chemicals	95,692,000	85,578,000.
Pentobarbital Phenazocine Phenmetrazine Phenmetrazine Phenylacetone Racemethorphan Racemorphan Remifentanil Recobarbital Rufentanil Repentatiol Phenylacetone Racemorphan Remifentanil Recobarbital Reference Remifentanil Repentation Remifentanil Remifentanil Repentation Remifentanil Repentation Remifentanil Remifentanil Repentation Remifentanil Remife	20,962,000	no change.
Phenazocine	3,395,280	
Phencyclidine Phenmetrazine Phenylacetone Racemethorphan Racemorphan Remifentanil Recobarbital Referentanil Repentadol Re	25,850,000	no change.
Phenmetrazine Phenylacetone Racemethorphan Racemorphan Remifentanil Recobarbital Referentanil Repentadol Repen	5	no change.
Phenylacetone Racemethorphan Racemorphan Remifentanil Recobarbital Respentation Repentation Remifentanil Repentation Remifentanil Repentation Remifentanil Repentation Remifentanil Remifen	35	no change.
Racemethorphan Racemorphan Remifentanil Recobarbital Resobarbital Resobarbital Remifentanil Repentation Remifentanil Remifentanil Repentation Remifentanil Remife	25	no change.
Racemorphan	40	no change.
Remifentanil Secobarbital Sufentanil apentadol Thebaine List I Chemicals	5	no change.
Secobarbital	5	no change.
Sufentanil	2,820	3,000.
apentadol	161,682	172,100.
List I Chemicals Sphedrine (for conversion)	1,880 18,388,280	no change. no change.
List I Chemicals Sphedrine (for conversion)	94,000,000	86,200,000.
phedrine (for conversion)	94,000,000	80,200,000.
	47.000	
	47,000	no change.
phedrine (for sale)	4,136,000	no change.
Phenylpropanolamine (for conversion)	14,100,000	no change.
Phenylpropanolamine (for sale)	7,990,000	no change.
Pseudoephedrine (for conversion)	40 180,000,000	1,000. no change.

The Acting Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Acting Administrator may adjust the

2018 aggregate production quotas and assessment of annual needs as needed.

Conclusion

After consideration of any comments or objections, or after a hearing, if one is held, the Acting Administrator will issue and publish in the **Federal Register** a final order establishing any adjustment of 2018 aggregate production quotas for each basic class of controlled substances in schedules I and II and established assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 21 CFR 1303.13(c) and 1315.13(f). Dated: August 17, 2018.

Uttam Dhillon,

Acting Administrator.

[FR Doc. 2018-18265 Filed 8-22-18; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement

Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Fisher Clinical Services, Inc Unither Manufacturing LLC	83 FR 28663 83 FR 29136	June 20, 2018. June 22, 2018.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies.

Dated: August 17, 2018.

John J. Martin,

Assistant Administrator.

[FR Doc. 2018–18266 Filed 8–22–18; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Greg N. Rampey, D.O.; Dismissal of Proceedings

On October 27, 2017, the Acting Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Greg N. Rampey, D.O. (Registrant), of Tulsa, Oklahoma. The Show Cause Order proposed the revocation of Registrant's DEA Certificate of Registration No. BR7006085 on the ground that he has

"no state authority to handle controlled substances" in the State of Oklahoma, the State in which he is registered with the DEA. Order to Show Cause, Government Exhibit (GX) 2, at 1, 2 (citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also proposed the denial of any of Registrant's "applications for renewal or modification of such registration and any applications for any other DEA registrations." *Id.* at 1.

With respect to the Agency's jurisdiction, the Show Cause Order alleged that Registrant is the holder of Certificate of Registration No. BR7006085, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of 8596 E. 101st, Ste. B, Tulsa, Oklahoma. *Id.* The Order also alleged that this registration does not expire until April 30, 2018. *Id.*

As the substantive ground for the proceeding, the Show Cause Order alleged that "on September 21, 2017, the Oklahoma State Board of Osteopathic Examiners cancelled [Registrant's] osteopathic medical license" and his "Oklahoma Bureau of Narcotics and Dangerous Drugs registration is inactive." Id. at 1–2. The Show Cause Order thus alleged that Registrant is "currently without authority to practice medicine or handle controlled substances in the State of Oklahoma, the [S]tate in which [he is] registered with the DEA," and that, as a consequence, "DEA must revoke" his registration. Id. at 2.

The Show Cause Order notified Registrant of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. *Id.* (citing 21 CFR 1301.43). The Order also notified Registrant of his right to submit a corrective action plan. *Id.* at 2–3 (citing 21 U.S.C. 824(c)(2)(C)).

According to an Affidavit of Service filed in this matter, on October 30, 2017, personnel from DEA's Office of Chief Counsel, Diversion and Regulatory Litigation Section, attempted to serve the Show Cause Order on the Registrant by regular first class mail addressed to the Registrant at his registered address. GX 6. The Government represents that its mailing was not returned as undeliverable. Id. On January 10, 2018, the Government submitted a Request for Final Agency Action (RFAA) representing that Registrant did not request a hearing and "ha[d] not filed any written statement in lieu of a hearing" within 30 days of service and seeking a final order revoking his registration. GX 7, at 2.

On February 6, 2018, the then-Acting Administrator issued an Order noting that the Government's effort at service in this case was "a departure from the Agency's traditional practice." GX 8. The Order further noted that "the Government cites to no authority establishing that a sole effort of mailing by first class mail (with no evidence of delivery to the address) is sufficient to provide constitutionally adequate service for initiating a proceeding under the Due Process Clause." *Id.* As a result, the then-Acting Administrator directed the Government to either address why its effort was consistent with the Due Process Clause or to engage in additional reasonable efforts to serve Registrant. Id.

On March 29, 2018, my office received the Government's Second Request for Final Agency Action (SRFAA) describing a Diversion Investigator's additional attempts to serve the Show Cause Order and again seeking a final order revoking Registrant's registration. SRFAA, at 2.